JPMorgan Chase Financial Company LLC, a wholly owned subsidiary of JPMorgan Chase & Co., has announced the pricing of its Uncapped Accelerated Barrier Notes on July 8, 2024. The notes, valued at $1,333,000, are linked to the performance of the Dow Jones Industrial Average and the S&P 500 Index and are set to mature on July 13, 2027. These structured investments are designed for investors seeking a 1.35 times return on any appreciation of the lesser performing index at maturity, with a minimum investment of $1,000. However, investors should be prepared to forgo dividends and interest payments and accept the potential loss of principal if the indices perform poorly. The notes are unsecured and unsubordinated obligations of JPMorgan Financial, with payments fully and unconditionally guaranteed by JPMorgan Chase...Show More

JPMorgan Chase Financial Company LLC, a wholly owned subsidiary of JPMorgan Chase & Co., has announced the pricing of its Uncapped Accelerated Barrier Notes on July 8, 2024. The notes, valued at $1,333,000, are linked to the performance of the Dow Jones Industrial Average and the S&P 500 Index and are set to mature on July 13, 2027. These structured investments are designed for investors seeking a 1.35 times return on any appreciation of the lesser performing index at maturity, with a minimum investment of $1,000. However, investors should be prepared to forgo dividends and interest payments and accept the potential loss of principal if the indices perform poorly. The notes are unsecured and unsubordinated obligations of JPMorgan Financial, with payments fully and unconditionally guaranteed by JPMorgan Chase & Co. The notes priced at $1,000 each, with an estimated value at the time of terms setting at $991.90 per note. The offering highlights various risks, including credit risks of JPMorgan Financial and JPMorgan Chase & Co., the potential loss of principal, and market volatility. The notes are not bank deposits, are not FDIC insured, and involve a number of risks detailed in the accompanying prospectus supplement and product supplement.